Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Inc. is a healthcare company developing pharmaceutical and medical device products for dermatology and wound care. It is headquartered in Westlake Village, California, and was founded in 2015.

The company's core technology is PermaFusion, a patented mixing process that keeps water-soluble active ingredients suspended in oil-based carriers without emulsifiers. Turn says the approach can allow lower amounts of active ingredients, and the platform has been used in medical device products cleared by the FDA. Its formulations include Hexagen, which suspends antimicrobial and anti-inflammatory compounds in petrolatum.

Turn Therapeutics is focused on dermatological conditions, including moderate to severe eczema and nail fungus, alongside wound care applications. The company became publicly traded on Nasdaq in 2025 through a direct listing.